323 related articles for article (PubMed ID: 25037253)
1. Epidemiology of severe drug hypersensitivity.
Dodiuk-Gad RP; Laws PM; Shear NH
Semin Cutan Med Surg; 2014 Mar; 33(1):2-9. PubMed ID: 25037253
[TBL] [Abstract][Full Text] [Related]
2. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: A 9-year experience in a tertiary care paediatric hospital setting.
Liccioli G; Mori F; Parronchi P; Capone M; Fili L; Barni S; Sarti L; Giovannini M; Resti M; Novembre EM
Clin Exp Allergy; 2020 Jan; 50(1):61-73. PubMed ID: 31608511
[TBL] [Abstract][Full Text] [Related]
3. Severe cutaneous adverse reactions to drugs.
Duong TA; Valeyrie-Allanore L; Wolkenstein P; Chosidow O
Lancet; 2017 Oct; 390(10106):1996-2011. PubMed ID: 28476287
[TBL] [Abstract][Full Text] [Related]
4. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
5. Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions.
Guvenir H; Arikoglu T; Vezir E; Misirlioglu ED
Curr Pharm Des; 2019; 25(36):3840-3854. PubMed ID: 31696807
[TBL] [Abstract][Full Text] [Related]
6. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
[TBL] [Abstract][Full Text] [Related]
7. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse drug reactions.
Teo YX; Walsh SA
Clin Med (Lond); 2016 Feb; 16(1):79-83. PubMed ID: 26833523
[TBL] [Abstract][Full Text] [Related]
9. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of cutaneous adverse drug reactions.
Mockenhaupt M
Chem Immunol Allergy; 2012; 97():1-17. PubMed ID: 22613850
[TBL] [Abstract][Full Text] [Related]
11. A retrospective, 5-year, clinicoepidemiological study of severe cutaneous adverse reactions (SCARs).
Singh GK; Mitra B; Arora S; Akhoon N; Verma R; Sharma P; Mitra D
Int J Dermatol; 2021 May; 60(5):579-588. PubMed ID: 33454956
[TBL] [Abstract][Full Text] [Related]
12. Drug Hypersensitivity Reactions.
Wilkerson RG
Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
[TBL] [Abstract][Full Text] [Related]
13. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
14. An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.
Gelincik A; Cavkaytar O; Kuyucu S
Curr Pharm Des; 2019; 25(36):3881-3901. PubMed ID: 31692425
[TBL] [Abstract][Full Text] [Related]
15. Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?
Horcajada-Reales C; Pulido-Pérez A; Suárez-Fernández R
Actas Dermosifiliogr; 2016; 107(1):23-33. PubMed ID: 26520037
[TBL] [Abstract][Full Text] [Related]
16. Severe cutaneous adverse reactions.
Hung SI; Mockenhaupt M; Blumenthal KG; Abe R; Ueta M; Ingen-Housz-Oro S; Phillips EJ; Chung WH
Nat Rev Dis Primers; 2024 Apr; 10(1):30. PubMed ID: 38664435
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms with skin eruptions mimicking acute generalized exanthematous pustulosis.
Goto T; Kogure A; Kuwano Y
J Dermatol; 2022 Jan; 49(1):e16-e17. PubMed ID: 34626006
[No Abstract] [Full Text] [Related]
18. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
20. Acute generalized exanthematous pustulosis and Stevens-Johnson syndrome overlap due to hydroxychloroquine: a case report.
Coleman I; Ruiz G; Brahmbhatt S; Ackerman L
J Med Case Rep; 2020 Nov; 14(1):210. PubMed ID: 33138853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
